5 reasons why no one has built a better EpiPen
[...] But critics say Mylan has little incentive to improve EpiPens: “If you’re the monopolist, and you’ve got a product that expires every year, and it’s not super easy to carry around so the safest thing to do is have several tucked away in different places — I don’t see why there would be any pressure to innovate,” said Nicholson Price, an assistant professor at the University of Michigan Law School who studies health care regulation and patent law.
“EpiPen’s flaws seem like features, not a bug,” Price said. [...]
Read the Full Article
Tags
fda health care finance innovation intellectual property pharmaceuticals public health regulation w. nicholson price ii